MedTrace Logo

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

NCT06599684 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-01-27

No results posted yet for this study

Summary

Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR \[Part 1\] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR \[Part 2\].

Conditions

  • Non-center Involved Diabetic Macular Edema
  • Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
  • Diabetic Retinopathy
  • Center-involved Diabetic Macular Edema
  • Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Interventions

DRUG

INV-102

0.7% Ophthalmic Solution

Sponsors & Collaborators

  • Invirsa, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Shalwitz · Invirsa, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-07
Primary Completion
2025-09-30
Completion
2025-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06599684 on ClinicalTrials.gov